Aurora Cannabis Launches 1.2g Resin Cartridges In Australia, Now Available For Doctors To Prescribe
Portfolio Pulse from Nina Zdinjak
Aurora Cannabis Inc. (NASDAQ: ACB) has launched its premium 1.2g resin cartridges in Australia, in partnership with MedReleaf Australia. These cartridges are now available for doctors to prescribe to patients. The products are developed at Aurora's EU-GMP and TGA-GMP certified facility and include offerings from both Aurora and IndiMed brands. Aurora's shares traded 0.98% higher at $5.92 during Wednesday's pre-market session.
June 05, 2024 | 2:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aurora Cannabis has launched its premium 1.2g resin cartridges in Australia, which are now available for doctors to prescribe. This expansion into the Australian market could boost Aurora's revenue and market presence.
The launch of new products in a new market (Australia) is likely to positively impact Aurora Cannabis's revenue and market presence. The stock price has already shown a slight increase in pre-market trading, indicating positive investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100